Abstract
Introduction
Antibodies (Ab) to the thyroid-stimulating hormone receptor (TSHR) may mimic [1] [2] [3] or block [4] the action of TSH or be functionally neutral [5] . TSHR stimulating Ab (TSAb) are responsible for many of the clinical manifestations of Graves' disease (GD) and are specific biomarkers [6] [7] [8] [9] [10] of this autoimmune thyroid disease (AITD). On the other hand, TSHR blocking Ab (TBAb) can also be found in AITD patients and may contribute to the hypothyroidism or atypical Hashimoto's thyroiditis (HT). Ever since the different functional activities of TSHR Ab have been recognized it has been suspected that certain patients might contain both TSAb and TBAb, and that this might explain the spectrum of clinical presentations. Indeed, recent evidence has proven that a patient can have both TSAb and TBAb by isolating monoclonal antibodies (MAb) with stimulatory and blocking activity from the lymphocytes of the same patient [11] . The measurement of TSAb and TBAb has potential clinical implications in the differential diagnosis of AITD, in predicting the outcome of GD after antithyroid drug treatment, in evaluating the risk of extrathyroidal manifestations of GD during pregnancy, and in predicting the likelihood of fetal/neonatal hyper-or hypothyroidism [10, 12] . TSHR Ab can be measured with either a bioassay or a binding assay. However, bioassays have the advantage of indicating not only the presence of Ab but also their functional activity and potency.
Since no studies that compare the performance of TSHR Ab immunoassays are available, we aimed to measure the lowest possible Ab concentration in several immunoassays and to compare the performance of ELISA and automated assays. FDA-cleared and/or validated functional cell-based bioassays for the measurement of TSHR Ab, whose analytical performance has been published [13] [14] [15] , were used for assay comparison. In the second part of this work, 2 human TSHR MAb were tested on an automated assay and an ELISA assay with regard to specific TSHR Ab functionality. Thus, in this study both patient sera containing polyclonal Ab and human MAb were applied.
Material and Methods
A total of 40 well-characterized patients with AITD were enrolled in this study. Samples were collected from 3 institutions (Johannes Gutenberg University [JGU] Medical Center, Mainz, Germany; Medical University of Bialystok, Poland; and UZ Leuven, Belgium) while measurements were performed in 2 laboratories (JGU and Prof. Wüster, Mainz). HT was defined as a serum level of anti-thyroid peroxidase Ab above the reference range with or without increased serum concentration of anti-thyroglobulin Ab, a hypoechoic appearance at thyroid ultrasound, and euthyroidism or hypothyroidism. GD was defined as positive TSHR Ab, suppressed baseline TSH, elevated free thyroid hormones (free triiodothyronine, fT3 and/or free thyroxine, fT4), and enhanced vascularization at thyroid ultrasound ("thyroid inferno"), with or without clinically manifestations of orbital disease. The study protocol was approved by the JGU Ethics Committee and was carried out in accordance with the ethical guidelines of the Helsinki Declaration. Informed consent was obtained from all participants investigated in the study.
Thyroid-Related Hormones and Antibodies
Serum concentrations of TSH, fT3, fT4, anti-thyroglobulin, and anti-thyroid peroxidase Ab were evaluated using electrochemiluminescence immunoassays (CLIA; Abbott, Wiesbaden, Germany) according to the manufacturer's instructions. For the diagnosis of GD, serum samples were measured for thyroid-binding inhibitory immunoglobulins (TBII) with the Cobas e411 analyzer, Elecsys (Roche Diagnostics, Mannheim, Germany). For the dilution analysis, TBII concentrations were measured with 4 different binding assays: Kronus (Star, ID, USA), Immulite 2000 XPi (Siemens, Erlangen, Germany), Kryptor (ThermoFisher, Hennigsdorf, Germany), and DS2 (Dynex, TECOmedical, Bünde, Germany). All binding assays were performed according to the manufacturer's instructions.
TSHR Stimulating and Blocking Antibody Bioassays
Serum TSAb activity was measured with a chimeric TSHR bioassay (Quidel Corp., San Diego, CA, USA) according to manufacturer's instructions [13, 14, 16] . TSAb activity was reported as percentage of specimen-to-reference ratio (SRR%) (cutoff SRR% <140). Serum TBAb activity was measured as described previously [15, 17] . Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine TSH alone (cutoff <40% inhibition). All bioassay measurements were done in duplicate. Both bioassays have been validated [13] [14] [15] , and the standardization of the TSAb bioassay was previously reported [16] .
Serial Dilution Analysis
The TSAb bioassay was compared with the TBII assays using 30 serum samples from 30 untreated patients with GD. Serial 1:3 dilutions were performed on each serum sample (200 μL) in duplicate into human TSAb-negative control serum (400 μL collected from a euthyroid, healthy subject devoid of thyroid, autoimmune, and oncological disease) up to a final dilution of 1:81. For samples still positive at 1:81, the dilution was extended to a final dilution of 1:243, 1:729 or 1:2,187.
Detection of Various Human TSHR MAb Mixtures with Stimulating (M22) and Blocking MAb (K1-70) Activities
MAb mixtures were diluted in control serum (collected from a healthy subject devoid of thyroid and autoimmune disease) with 20 ng/mL of TSAb M22 (Kronus) and 200 ng/mL of TBAb K1-70 (Kronus) at different ratios. Mixtures of 100% K1-70 (200 ng/mL), 80% K1-70 (160 ng/mL) + 20% M22 (4 ng/mL), 60% K1-70 (120 ng/mL) + 40% M22 (8 ng/mL), 40% K1-70 (80 ng/mL) + 60% M22 Eur Thyroid J 2017;6:243-249 DOI: 10.1159/000478522 (12 ng/mL), 20% K1-70 (40 ng/mL) + 80% M22 (16 ng/mL), and 100% M22 (20 ng/mL) were prepared and measured in the TBAb bioassay and Immulite and Kronus assays following the manufacturers' instructions. 
Statistical Analysis

Results
The demographic and serological data of all 40 investigated patients with AITD are summarized in Table 1 . Thirty well-characterized, untreated, hyperthyroid TSAb-positive/TBAb-negative patients with GD were included as well as 10 euthyroid (on levothyroxine) TBAbpositive/TSAb-negative patients with either GD or HT.
Assay Performance
The number of positive samples in all 30 hyperthyroid patients with GD, undiluted and at each dilution step (1:3 to 1:2,187), measured in the TSAb bioassay and the Immulite, Kryptor, and 2 Kronus and Dynex ELISA assays are shown in Figure 1 In the dilution analysis, samples were positive until dilution 1:2,187 in the TSAb bioassay, 1:81 in the Immulite (p < 0.002 vs. bioassay) and Kronus ELISA (p = 0.039) assays, and 1:27 in the Kryptor and Dynex ELISA (p < 0.001 vs. bioassay). The TSAb bioassay and TBII binding assay median and interquartile (25th and 75th percentile) values for 40 undiluted serum samples from patients with either GD or HT are shown in Table 2 . Overall, the sample dilution study showed higher detection sensitivity for the TSAb bioassay. K1-70 (160 ng/mL) + 20% M22 (4 ng/mL), 60% K1-70 (120 ng/mL) + 40% M22 (8 ng/mL), 40% K1-70 (80 ng/ mL) + 60% M22 (12 ng/mL), 20% K1-70 (40 ng/mL) + 80% M22 (16 ng/mL), and 100% M22 (20 ng/mL) all tested positive in both the Immulite (26.4, 20.2, 15.2, 10.5, 6.3, 2.00 IU/L) (Fig. 2c) (Fig. 2d) . Overall, the antibody mixture study demonstrated higher specificity of the bioassays over the binding assays.
Discussion
This original study compared for the first time the assay performance and dilution analysis of 6 immunoassays using well-characterized serum samples from clearly defined patients with AITD. This comparative immunoassay study encompassed both newly introduced automated binding assays, widely distributed ELISA assays, and FDA-cleared and/or validated cell-based bioassays. The TBII, thyroid-binding inhibitory immunoglobulins; TSAb, thyroid-stimulating hormone receptor stimulating Ab; TBAb, thyroid-stimulating hormone receptor blocking Ab; SRR%, specimen-to-reference ratio. direct comparison demonstrated significant differences in the performance of the 6 assays. The most striking difference was the higher sensitivity of the cell-based TSAb bioassay, which remained positive both at the highest dilution of sera and at the lowest antibody concentration. Surprisingly, the performance was better in an ELISA assay, using the MAb M22 as a ligand to the TSHR, compared to the latest generation of automated TSHR Ab binding assays. All patients with AITD were carefully selected according to the diagnoses of GD and HT defined in the recently published guidelines of the American Thyroid Association (ATA) on hyperthyroidism management [18] . The serum samples from untreated patients with GD AITD, autoimmune thyroid disease; TSAb, thyroid-stimulating hormone receptor stimulating Ab; TBAb, thyroid-stimulating hormone receptor blocking Ab; SRR%, specimen-to-reference ratio. were tested and reproduced at least 3 times in the TSAb bioassay. Marked and statistically significant differences were then noted in the undiluted patient serum samples between the TSAb bioassay and 2 out of 4 binding assays. A significant lower accuracy and sensitivity was observed, especially between the bioassay and the Kryptor and Dynex assays. Furthermore, the dilution analysis demonstrated marked differences between the bioassay and all 4 binding assays at high dilutions. In comparison, a dilution analysis of 20 untreated patients with GD selected from a prospective trial with antithyroid drug treatment demonstrated large and significant differences between the bioassay and the automated Cobas binding assay, with 250-to 800-fold differences of magnitude pertaining to the limit of detection, limit of quantitation, and half-maximal effective concentration, EC 50 [14] . To the best of our knowledge, there are no other studies on dilution analysis that allow a direct comparison of results from multiple commonly used anti-TSHR assays.
The considerably higher performance of the bioassays could be clinically relevant in a number of circumstances, such as in patients with low serum TSHR Ab levels which may be observed in mild and/or subclinical thyroid dysfunction, in recent onset of GD, and in the euthyroid variant of orbitopathy. Furthermore, it has been reported that both children [19] and adults with euthyroid orbitopathy [10, 20, 21] can test positive for TSAb and negative for TBII. Greater assay sensitivity might also lead to improved follow-up during the medical management of patients with Graves' hyperthyroidism and timing of treatment cessation. Accurate measurement of these Ab at the end of the usual 1-year treatment period would be clinically useful in deciding whether or not to terminate treatment.
The second part of this work showed the exclusive capability of the bioassays to specifically identify TSHR Ab functionality. Indeed, only bioassays were able to exclusively differentiate between TSHR stimulating and blocking Ab activity. For example, 10 samples from well-defined patients with AITD were positive for TSHR blocking Ab and negative for TSHR stimulating Ab in the cell-based bioassays. However, all patients tested positive in the automated (Immulite and Kryptor) and ELISA (Kronus and Dynex) binding assays. Distinguishing between TSAb and TBAb is relevant for accurate diagnostic and therapeutic management of AITD, especially during the critical period of pregnancy and postpartum, during AITD progression, and during the medical management of patients with Graves' hyperthyroidism. Both a shift from stimulatory to blocking activity during pregnancy [22] and spontaneous changes of TSHR Ab functionality [23] have been described. Within a large prospective trial in patients with GD performed at our institution, medical antithyroid treatment led to either a shift of Ab functionality and/or the appearance of both stimulating and blocking TSHR Ab in approximately 10% of the treated patients [24] . Also, the presence of blocking TSHR Ab had a significant impact on the probability of remission. Finally, blocking TSHR Ab caused hypothyroidism in patients with AITD, foremost in HT [25, 26] .
In summary, the results obtained in the present study support both superior performance and exclusive functional Ab specificity of the cell-based bioassays compared to novel automated and widely distributed ELISA binding assays. These results have implications for the clinical management of patients with AITD.
